GSK:LSEGSK plc Analysis

GSK shares are trading at £2,046, comfortably above the 20‑day (£2,166) and 50‑day (£2,001) SMAs but still above the 200‑day SMA (£1,676), indicating a lingering bullish bias despite a recent pull‑back toward support at £1,987.5. The RSI sits at 42.8, suggesting neutral momentum, while the MACD histogram is negative (‑31.3) and the signal line is bearish, warning of short‑term downside pressure. Volatility is elevated at 33% over the past 30 days, yet the beta of 0.11 signals very low systematic risk relative to the market. Fundamentally, the stock trades at a forward P/E of 10.4 versus an industry average of 25.4, and the dividend yield of 3.53% is supported by a modest payout ratio of 46%, implying sustainable income.
Recent material news underscores the narrative: specialty medicines delivered a 17% sales jump to £13.5 bn, driving a 7% overall revenue increase to £32.7 bn, and the acquisition of RAPT Therapeutics adds a late‑stage immunology asset to the pipeline. While the DCF‑derived fair value (£1,120) is well below the market price, the strong cash generation (free cash flow £3.28 bn) and high ROE (43%) suggest the market may be pricing in future growth rather than current fundamentals. Overall, the stock appears overvalued on a discounted cash‑flow basis but benefits from solid earnings momentum, a robust dividend, and a low‑beta defensive profile.